Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
IMMNOV Stock Overview
Immunovia AB (publ), a diagnostic company, develops and commercializes blood tests in Sweden and internationally.
Immunovia Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr29.78 |
52 Week High | kr141.50 |
52 Week Low | kr22.10 |
Beta | 1.53 |
1 Month Change | -21.88% |
3 Month Change | -23.64% |
1 Year Change | -70.37% |
3 Year Change | -82.25% |
5 Year Change | -73.41% |
Change since IPO | 0.27% |
Recent News & Updates
Is Immunovia (STO:IMMNOV) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Shareholder Returns
IMMNOV | SE Medical Equipment | SE Market | |
---|---|---|---|
7D | -3.0% | 0.6% | -2.9% |
1Y | -70.4% | -37.2% | -25.5% |
Return vs Industry: IMMNOV underperformed the Swedish Medical Equipment industry which returned -37.2% over the past year.
Return vs Market: IMMNOV underperformed the Swedish Market which returned -25.5% over the past year.
Price Volatility
IMMNOV volatility | |
---|---|
IMMNOV Average Weekly Movement | 14.4% |
Medical Equipment Industry Average Movement | 7.8% |
Market Average Movement | 7.4% |
10% most volatile stocks in SE Market | 12.2% |
10% least volatile stocks in SE Market | 4.7% |
Stable Share Price: IMMNOV is more volatile than 90% of Swedish stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: IMMNOV's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 69 | Philipp Mathieu | https://www.immunovia.com |
Immunovia AB (publ), a diagnostic company, develops and commercializes blood tests in Sweden and internationally. The company’s product includes IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. It also develops research projects for lung cancer.
Immunovia Fundamentals Summary
IMMNOV fundamental statistics | |
---|---|
Market Cap | kr673.97m |
Earnings (TTM) | -kr176.63m |
Revenue (TTM) | kr903.00k |
746.6x
P/S Ratio-3.8x
P/E RatioIs IMMNOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IMMNOV income statement (TTM) | |
---|---|
Revenue | kr903.00k |
Cost of Revenue | -kr3.01m |
Gross Profit | kr3.91m |
Other Expenses | kr180.54m |
Earnings | -kr176.63m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 24, 2022
Earnings per share (EPS) | -7.80 |
Gross Margin | 432.89% |
Net Profit Margin | -19,560.69% |
Debt/Equity Ratio | 0% |
How did IMMNOV perform over the long term?
See historical performance and comparisonValuation
Is IMMNOV undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IMMNOV?
Other financial metrics that can be useful for relative valuation.
What is IMMNOV's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | kr673.97m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 525.9x |
Enterprise Value/EBITDA | -2.7x |
PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does IMMNOV's PB Ratio compare to its peers?
IMMNOV PB Ratio vs Peers |
---|
Company | PB | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 6.4x | ||
QLINEA Q-linea | 6.3x | 22.2% | kr2.3b |
INTEG B Integrum | 5.2x | -64.2% | kr830.7m |
ICO Iconovo | 4.1x | 9.8% | kr522.0m |
BRAIN BrainCool | 9.9x | n/a | kr373.7m |
IMMNOV Immunovia | 1.7x | 48.6% | kr674.0m |
Price-To-Book vs Peers: IMMNOV is good value based on its Price-To-Book Ratio (1.7x) compared to the peer average (6.4x).
Price to Earnings Ratio vs Industry
How does IMMNOV's PE Ratio compare vs other companies in the SE Medical Equipment Industry?
Price-To-Book vs Industry: IMMNOV is good value based on its Price-To-Book Ratio (1.7x) compared to the Swedish Medical Equipment industry average (3.6x)
Price to Book Ratio vs Fair Ratio
What is IMMNOV's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PB Ratio | 1.7x |
Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate IMMNOV's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of IMMNOV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate IMMNOV's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate IMMNOV's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IMMNOV's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is Immunovia forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score
3/6Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
48.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMMNOV is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IMMNOV is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IMMNOV is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IMMNOV's revenue (58.9% per year) is forecast to grow faster than the Swedish market (5.4% per year).
High Growth Revenue: IMMNOV's revenue (58.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IMMNOV's Return on Equity is forecast to be very high in 3 years time (44%).
Discover growth companies
Past Performance
How has Immunovia performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-29.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IMMNOV is currently unprofitable.
Growing Profit Margin: IMMNOV is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IMMNOV is unprofitable, and losses have increased over the past 5 years at a rate of 29.3% per year.
Accelerating Growth: Unable to compare IMMNOV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMMNOV is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (6.3%).
Return on Equity
High ROE: IMMNOV has a negative Return on Equity (-45.63%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Immunovia's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: IMMNOV's short term assets (SEK249.4M) exceed its short term liabilities (SEK26.4M).
Long Term Liabilities: IMMNOV's short term assets (SEK249.4M) exceed its long term liabilities (SEK36.1M).
Debt to Equity History and Analysis
Debt Level: IMMNOV is debt free.
Reducing Debt: IMMNOV has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMMNOV has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IMMNOV has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 24.4% each year.
Discover healthy companies
Dividend
What is Immunovia current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IMMNOV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IMMNOV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IMMNOV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IMMNOV's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as IMMNOV has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
0.5yrs
Average management tenure
CEO
Philipp Mathieu
0.50
Tenure
Mr. Philipp Mathieu serves as Chief Executive Officer and President at Immunovia AB (publ) since June 02, 2022. Mr. Mathieu served as an Acting CEO & President of Immunovia AB (publ) since January 20, 2022...
Leadership Team
Experienced Management: IMMNOV's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.
Board Members
Experienced Board: IMMNOV's board of directors are considered experienced (5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Immunovia AB (publ)'s employee growth, exchange listings and data sources
Key Information
- Name: Immunovia AB (publ)
- Ticker: IMMNOV
- Exchange: OM
- Founded: 2007
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: kr673.968m
- Shares outstanding: 22.63m
- Website: https://www.immunovia.com
Number of Employees
Location
- Immunovia AB (publ)
- Medicon Village
- Scheelevägen 8
- Lund
- Skåne County
- 223 63
- Sweden
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/07/06 00:00 |
End of Day Share Price | 2022/07/06 00:00 |
Earnings | 2022/03/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.